Opus Genetics Inc (NASDAQ: IRD) kicked off on Friday, up 9.57% from the previous trading day, before settling in for the closing price of $1.15. Over the past 52 weeks, IRD has traded in a range of $0.81-$2.34.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
During the last 5-year period, the sales growth of Healthcare Sector giant was 1653.38%. While this was happening, its average annual earnings per share was recorded -143.48%. With a float of $24.22 million, this company’s outstanding shares have now reached $26.20 million.
Let’s determine the extent of company efficiency that accounts for 14 employees.
Opus Genetics Inc (IRD) Insider Activity
Our next focus will be how large-scale investors are participating in this stock of the Biotechnology Industry. The insider ownership of Opus Genetics Inc is 21.52%, while institutional ownership is 8.47%. The most recent insider transaction that took place on Dec 26 ’24, was worth 97,600. In this transaction Chief Executive Officer of this company bought 100,000 shares at a rate of $0.98, taking the stock ownership to the 599,150 shares. Before that another transaction happened on Nov 21 ’24, when Company’s President bought 10,000 for $0.98, making the entire transaction worth $9,834. This insider now owns 342,800 shares in total.
Opus Genetics Inc (IRD) Earnings and Forecasts
Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.29 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around -143.48% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will plunge by -1.78% during the next five years compared to 53.36% growth over the previous five years of trading.
Opus Genetics Inc (NASDAQ: IRD) Trading Performance Indicators
Take a look at Opus Genetics Inc’s (IRD) current performance indicators. Last quarter, stock had a quick ratio of 6.63. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 4.75.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -1.09, a number that is poised to hit -0.24 in the next quarter and is forecasted to reach -0.99 in one year’s time.
Technical Analysis of Opus Genetics Inc (IRD)
Looking closely at Opus Genetics Inc (NASDAQ: IRD), its last 5-days average volume was 0.54 million, which is a jump from its year-to-date volume of 0.19 million. As of the previous 9 days, the stock’s Stochastic %D was 85.52%. Additionally, its Average True Range was 0.09.
During the past 100 days, Opus Genetics Inc’s (IRD) raw stochastic average was set at 60.00%, which indicates a significant decrease from 92.72% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 85.56% in the past 14 days, which was lower than the 86.56% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $1.1054, while its 200-day Moving Average is $1.3104. However, in the short run, Opus Genetics Inc’s stock first resistance to watch stands at $1.3400. Second resistance stands at $1.4200. The third major resistance level sits at $1.5500. If the price goes on to break the first support level at $1.1300, it is likely to go to the next support level at $1.0000. Should the price break the second support level, the third support level stands at $0.9200.
Opus Genetics Inc (NASDAQ: IRD) Key Stats
The company with the Market Capitalisation of 39.78 million has total of 31,568K Shares Outstanding. Its annual sales at the moment are 19,050 K in contrast with the sum of -9,990 K annual income. Company’s last quarter sales were recorded 3,870 K and last quarter income was -7,530 K.
